11 results about "Respiratory chain" patented technology

The present application discloses a use of an endoperoxy compound in the preparation of an antimicrobial pathogenic bacteria drug. Under anaerobic conditions, in the culture medium of Mycobacterium tuberculosis, the representative artemisinin-based drug of the endoperoxy compound can partially and effectively inhibit the survival of Mycobacterium tuberculosis. The present application also discloses a use of an endoperoxy compound in combination with a respiratory chain inhibitor in the preparation of an antimicrobial pathogenic bacteria drug. Under normal and anaerobic conditions, in the culture medium of Mycobacterium tuberculosis, the endoperoxy compound and a variety of respiratory chain inhibitors have a synergistic effect, and the combined use has a more effective inhibitory effect on Mycobacterium tuberculosis. The endoperoxy compounds include artemisinin and its derivatives, as well as other endoperoxy compounds with a double oxygen bridge structure, which may have a similar mechanism of action, and the internal oxygen bridge is the key group for them to play a role. The present application aims to kill pathogens more quickly or effectively, improve the cure efficiency or shorten the course of treatment, overcome the problem of drug resistance, and reduce the amount of drugs to reduce side effects on patients by introducing endoperoxy compounds represented by artemisinin as drugs.

Provided is use of an endoperoxide in preparing an anti-microbial drug. In an anoxic condition, the endoperoxide can partially and effectively inhibit the survival of Mycobacterium tuberculosis. Provided is use of an endoperoxide in combination with a respiratory chain inhibitor in preparing an anti-microbial drug. The endoperoxide includes artemisinin and derivatives thereof, and other endoperoxides with a two-oxygen bridge structure. The endoperoxide has synergistic effects with a variety of respiratory chain inhibitors, and the combination has a more effective inhibition effect on Mycobacterium tuberculosis.

The construction and application of an intratumorally self-proliferating enhanced oncolytic microbial delivery system belongs to the field of pharmaceutical formulation technology. Through a synthetic reaction, a hydrogen sulfide donor is endowed with a membrane-intercalable regional structure. Then, a lipid membrane containing the membrane-intercalable hydrogen sulfide donor is used to encapsulate bacteria through self-assembly, thus preparing an intratumorally self-proliferating enhanced oncolytic microbial delivery system. After intravenous injection of the delivery system, it accumulates within the tumor. In the tumor inflammatory microenvironment, the hydrogen sulfide released by the donor can be converted into tetrathionate. Tetrathionate respiration is a unique form of respiration in Salmonella. Through both aerobic and tetrathionate respiration, the system specifically promotes the proliferation of Salmonella in the tumor site, thereby enhancing tumor cell pyroptosis and achieving anti-tumor effects. This invention provides a novel theory and advanced solution for cancer treatment, and also offers promising strategies and exploratory ideas for the clinical application of attenuated Salmonella, possessing significant scientific research value.

The invention belongs to the field of biology, and discloses a tissue formula preserving fluid containing antimycin A. The tissue formula preserving fluid comprises a basic culture medium, the basal culture medium contains superoxide dismutase, catalase and antimycin A. On the basis of the superoxide dismutase and the catalase, the preservation solution is matched with the antimycin A, so that the activity of tissue cells can be remarkably improved; in the research process, we have the following specificity that: 1, when the respiratory chain inhibitor drug is applied to the formula of the invention, the improvement degree of the cell viability of only antimycin A is the highest; 2, the function of antimycin A must be exerted based on the use of superoxide dismutase and catalase; meanwhile, the invention further provides a tissue preservation method.

This invention belongs to the field of biomedical technology, specifically relating to compounds for treating KRAS-mutant tumors and their uses. This invention provides compound 666-15, which provides dual inhibition of cytoplasmic-mitochondrial NAD5. + Transport (via targeting SLC25A51) and succinate dehydrogenase (SDH / complex II), while simultaneously disrupting mitochondrial NAD. + Transport and respiratory chain NAD + A novel therapeutic strategy to target KRAS-mutant tumors by utilizing regenerative functions.

The present invention relates generally to isolated mitochondria derived from mtDNA-depleted cells (RhoO-mito) that are advantageously used as delivery vehicles for heterogenous proteins or nucleic acids or chemical agents. In some embodiments, proteins or nucleic acids or chemical agents are introduced into a cell, transported into, transferred or expressed in the mitochondria, thereafter or before mtDNA is removed and mtDNA-free mitochondria are extracted from the cell. These mitochondria are used for therapeutic treatment of mitochondria-related diseases such as maple syrup syndrome, citrin deficiency, Nieman-Pick disease, X-linked adrenoleukodystrophy (X-ALD), Pyruvate Dehydrogenase Deficiency, respiratory chain diseases, mutations in mitochondrial respiratory chain proteins, fatty acid metabolism disorders, or cancer with reduced likelihood of causing an immunogenic response. Additionally, in some embodiments the present invention relates to isolated mitochondria, including but not necessarily isolated mitochondria derived from mtDNA-depleted cells (RhoO-mito), that are exogenously introduced into cells to enhance production of endogenous or heterogenous proteins.

The application discloses a Parkinson's disease targeted application of a pueraria exosome loaded with a mitochondria-activated miRNA, and belongs to the field of biological applications.The miRNA comprises at least one of miRNAs shown in sequences as shown in SEQ ID No, 1 to SEQ ID No, 23.The pueraria exosome and the miRNA delivered thereby in the application show a good treatment effect on Parkinson's disease, and mainly play a role in improving mitochondrial dysfunction, such as promoting mitochondrial autophagy, improving mitochondrial membrane potential, reducing oxidative stress, maintaining the integrity of the mitochondrial inner membrane respiratory chain, and increasing ATP generation.The application further discloses a delivery scheme of the pueraria-derived exosome as the miRNA carrier by using neuron-targeted modification, which can improve the targeting and stability of the miRNA, and overcome the problems of low miRNA drug delivery efficiency and easy degradation.The application is expected to promote the treatment process of Parkinson's disease through the neuron-targeted pueraria exosome and the miRNA delivered thereby.

This invention relates to the field of biopesticide technology, and particularly to a compound formulation for controlling pineapple root-knot nematodes, its preparation method, and its application. The aforementioned compound formulation for controlling pineapple root-knot nematodes comprises, by weight percentage: 0.1-5% azadirachtin or compound azadirachtin, 30-60% castor seed meal, 35-65% activated carbon, and the remainder being a binder. This invention uses a compound of activated carbon, azadirachtin, and castor seed meal. Azadirachtin achieves highly effective contact killing by inhibiting the nematode's respiratory chain and nerve signal transmission, without developing resistance. Activated carbon acts as a slow-release carrier, prolonging the efficacy (lasting for more than 90 days) and adsorbing soil toxins to improve the microenvironment. Castor seed meal provides organic matter to promote the proliferation of beneficial soil bacteria and improve soil structure; it is also rich in ricin, effectively inhibiting nematode egg hatching. The combined use of these three ingredients achieves synergistic effects through a triple mechanism of slow release, killing, and soil improvement.

The invention discloses rhodococcus capable of improving eggshell quality, uterine tissue damage and energy metabolism of old laying hens and application of the rhodococcus. The invention belongs to the field of microorganisms, and particularly relates to rhodococcus capable of improving eggshell quality, uterine tissue damage and energy metabolism of old laying hens and application of the rhodococcus. The Rhodococcus ruber disclosed by the invention is Rhodococcus ruber NML-01, and the registration number of the Rhodococcus ruber NML-01 in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms is CGMCC No.36760. The NML-01 strain can effectively increase the eggshell thickness of old laying hens, contributes to reducing the egg breaking rate and prolonging the egg laying cycle and economic utilization period of the laying hens, can reduce oxidative stress (MDA) and DNA damage (rH2AX) of uterine tissues, activates mitochondrial autophagy by up-regulating a PINK1 / PARK pathway, and improves the respiratory chain complex IV activity and ATP level.

This invention discloses a method for producing ethanol by fermentation of Saccharomyces cerevisiae based on a dual antimicrobial strategy. The method involves inhibiting the respiratory chain of contaminating microorganisms with cyanamide and utilizing the overexpression of the gene encoding cyanamide hydratase in Saccharomyces cerevisiae 1308. CAH To reduce the impact of cyanamide on Saccharomyces cerevisiae, this invention employs the antimicrobial peptide DptB and the endolysin LysKB317 to target and inhibit Acetobacter and Lactobacillus. This invention combines the chemical antimicrobial properties of cyanamide with the biological antimicrobial properties of the endolysin, forming a dual antimicrobial strategy in the fermentation process of Saccharomyces cerevisiae for ethanol production. The synergistic effect of chemical and biological antimicrobial action achieves an organic combination of broad-spectrum and targeted antimicrobial activity. This effectively inhibits contaminating bacteria while reducing interference with Saccharomyces cerevisiae metabolism caused by chemical antimicrobial agents, thus lowering the risk of contamination during industrial ethanol production. Ultimately, it improves the stability and economic efficiency of ethanol production, increasing the ethanol yield of the 50–200 g / L glucose fermentation system by 10.1%–23.7% compared to the control group.

The invention discloses a cell factory for efficiently producing squalene, which is characterized in that a squalene engineering strain SquMC13 with'cytoplasm-mitochondria 'dual regulation and control in a laboratory is taken as an original strain, a plurality of modification strategies associated with relieving Crab tree are tried, and a plurality of saccharomyces cerevisiae gene engineering strains are screened from the original strain and comprise saccharomyces cerevisiae gene engineering strains C12, C15, C34, C41 and C46; wherein the squalene production capacity of the saccharomyces cerevisiae genetic engineering strain C46 is most prominent, and the squalene yield fermented by a 5-liter bioreactor is up to 57.21 g / L. According to the gene modification disclosed by the invention, the carbon flow is promoted to enter a respiratory chain and TCA circulation, and meanwhile, the metabolism steady state of cells is effectively improved by means of mitochondrial function enhancement, cell robustness improvement and the like, so that a new technical approach is provided for realizing efficient production of squalene under industrial conditions.